Data Foundry

Drug recalls 2022

Tacrolimus Ointment — Class III drug recall D-1304-2022

Ongoing recall by Glenmark Pharmaceuticals Inc., USA, reported 2022-08-10, distributed nationwide. Defective Container: Tube split from side seam

Recall numberD-1304-2022
Product typeDrug
ClassificationClass III
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmGlenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States
Recall initiated2022-07-11
Classified2022-08-04
Reported by FDA2022-08-10
DistributedNationwide (US)
Quantity654,756 tubes
Reason classespackaging
NDC68462-0534, 68462-0534-35, 68462-0534-65, 68462-0534-94, 68462-0881, 68462-0881-35, 68462-0881-65, 68462-0881-94
Expiration dates2022-06, 2022-07, 2022-08, 2022-09, 2022-10, 2022-11, 2022-12, 2023-01, 2023-02, 2023-03, 2023-04, 2023-05, 2023-06, 2023-07, 2023-08, 2023-09, 2023-10, 2023-11, 2023-12, 2024-01, 2024-02, 2024-03

Product

Tacrolimus Ointment, 0.1%, For Dermatological Use Only, Not for Ophthalmic Use, Rx Only, a) 30 g tube, NDC 68462-534-35, b) 60 g tube, NDC 68462-534-65, c) 100 g tube, NDC 68462-534-94, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India.

Reason for recall

Defective Container: Tube split from side seam

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1304-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.